drugset
drugset / Trial / NCT05119790

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

NCT05119790 ↗

Phase 1 Completed 7 enrolled Biogen Denali Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, non-randomized, open-label Phase 1 study to determine the absorption, metabolism, and excretion (AME) of BIIB122 (DNL151) following administration of a single oral dose of \[14C\] BIIB122 (\[14C\] DNL151) following a fast. The mass balance, excretion, and PK of BIIB122 (DNL151) will be used to evaluate AME.

Timeline

Start
2021-08-27
Primary completion
2021-11-05
Completion
2021-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB122 Small molecule — Oral

Indications

No indication recorded.